Dishing The Science with Dr. Sue

Improving quality of life is a central goal in successful weight management.  Do weight loss medications improve quality of life? Are there situations where quality of life could get worse, rather than better? 

Learn more: https://drsue.ca/2025/09/do-weight-management-medications-improve-quality-of-life/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

While we now have several injectable GLP-1s based treatments for weight management around the world [liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Zepbound/Mounjaro)], there are no GLP-1s currently available in a pill format for obesity treatment. But that is likely soon to change, backed by a whirlwind of data that have come out around orforglipron and oral semaglutide this week. What will this mean for people seeking weight management treatment?

Learn more: https://drsue.ca/2025/09/glp-1-in-a-pill-for-weight-loss-pinning-down-where-were-at/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Two out of three people with type 2 diabetes have 'fatty liver disease' (now called MASH/MASLD).  Should everyone with prediabetes or type 2 diabetes be screened? Find out what the brand new Diabetes Canada Guidelines say here!

Learn more: https://drsue.ca/2025/09/does-everyone-with-type-2-diabetes-need-to-be-screened-for-mash-masld-fatty-liver-what-the-new-diabetes-canada-guidelines-recommend/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Metformin has lots of benefits, including a reduction in inflammation.  Is the reduction in inflammation enough to reduce pain in knee osteoarthritis? 

Learn more: https://drsue.ca/2025/09/could-metformin-improve-knee-osteoarthritis-pain/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Can semaglutide (Wegovy), tirzepatide (Mounjaro/Zepbound), or liraglutide (Saxenda) benefit liver health - and what did we recommend in our new 2025 Obesity Canada Pharmacotherapy Clinical Practice Guidelines? Find out here!

Learn more: https://drsue.ca/2025/08/do-glp1-based-weight-management-medications-benefit-liver-health/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Some people on weight management medication may want to stop treatment because of cost, or perhaps because they want to again try 'doing it on their own'. What do our new Obesity Canada 2025 Clinical Practice Guidelines recommend on this topic?

Learn more: https://drsue.ca/2025/08/what-happens-if-you-stop-weight-management-medication-and-what-do-our-new-obesity-canada-guidelines-advise/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

As the lead author, I am thrilled to ANNOUNCE publication of our long-awaited 2025 Obesity Canada Clinical Practice Guidelines!  Includes 13 recommendations, a brand new Decision Tool&Table to guide in the choice of medication, Key Messages for Health Care Professionals and Key Messages for People With Obesity. ENJOY!! 

Learn more: https://drsue.ca/2025/08/obesity-canada-pharmacotherapy-clinical-practice-guidelines-2025-published/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

In our NEW 2025 Obesity Canada Pharmacotherapy Clinical Practice Guidelines, we identified many existing gaps where data is lacking. Where did our Guidelines leave us wanting for more? Where is more research needed? Find out here!

Learn more: https://drsue.ca/2025/08/obesity-canada-2025-pharmacotherapy-guidelines-what-couldnt-we-answer/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Erectile dysfunction (ED) is common in men with elevated weight. Can weight loss medications improve ED?

Learn more: https://drsue.ca/2025/08/can-weight-loss-medications-improve-erectile-dysfunction-ed/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

In choosing the best GLP1-based medication for our patients with type 2 diabetes at high risk of cardiovascular disease, guidelines recommend choosing one that has proven reduction in risk of CV events in cardiovascular outcome trials (CVOTs). High level results just released on Mounjaro's SURPASS CVOT study tell us how mounjaro stacks up. Read on to find out!

Learn more: https://drsue.ca/2025/08/how-does-mounjaro-stack-up-for-cardiovascular-protection-the-surpass-cvot-results/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.